title: [First-line therapy in advanced renal cell carcinoma : A randomized phase II study to examine early switch of tyrosine kinase inhibitors to nivolumab compared to continued tyrosine kinase inhibitor therapy in patients with advanced or metastatic renal cell carcinoma and stable disease after three months of treatment (NIVOSWITCH)-AN 38/15 of the AUO].
authors.affiliation: Geschäftsstelle der AUO, MeckEvidence - Dienstleistungen für medizinische Dokumentation und Forschung, Seestr. 11, 17252, Schwarz, Deutschland. auo.presse@MeckEvidence.de.
authors.forename: H
authors.initials: H
authors.lastname: Rexer
authors.affiliation: Organgruppe Nierenzellkarzinom der Arbeitsgemeinschaft Urologische Onkologie in der Deutschen Krebsgesellschaft e. V., Kuno-Fischer-Str. 8, 14057, Berlin, Deutschland.
authors.forename: Th
authors.initials: T
authors.lastname: Steiner
authors.affiliation: Klinik für Hämatologie, Hämostasiologie und Onkologie, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, 30625, Hannover, Deutschland.
authors.forename: V
authors.initials: V
authors.lastname: Grünwald
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000074322:Antineoplastic Agents, Immunological / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000473:pathology; D018572:Disease-Free Survival; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000473:pathology; D009362:Neoplasm Metastasis / Q000188:drug therapy* / Q000473:pathology; D000077594:Nivolumab / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D012720:Severity of Illness Index; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D000074322:Antineoplastic Agents, Immunological; D047428:Protein Kinase Inhibitors; D000077594:Nivolumab; D011505:Protein-Tyrosine Kinases